MUMBAI, India, Jan. 9 -- Intellectual Property India has published a patent application (202511112664 A) filed by Kiet Group Of Institutions, Ghaziabad, Uttar Pradesh, on Nov. 17, 2025, for 'development of a rp-hplc method for estimation of tizanidine hydrochloride in pharmaceutical dosage form.'
Inventor(s) include Ritika Saini; Ms. Surbhi Kamboj; Dr. Monika Kaurav; and Dr. K. Nagarajan.
The application for the patent was published on Jan. 9, under issue no. 02/2026.
According to the abstract released by the Intellectual Property India: "This invention provides a RP-HPLC method which is newly crafted and verified for its accuracy, speed, and precision in estimating Tizanidine Hydrochloride in pharmaceuticals. The Tizanidine RP-HPLC method utilized a C18 column and used a mobile phase of 80:20 v/v acetonitrile and phosphate buffer (pH 7.5) at a 1.5 mL/min flow rate and 230 nm UV detection. The system motif's parameters indicate confidence levels. The method describes and displays with well-defined peaks at 2.6 minutes. Adhering with the ICH Q2 guidelines, the method was confirmed for its well-defined precision, accuracy, and sensitivity (LOD 0.63 ppm, LOQ 1.93, LQS ppm) while maintaining an R2 greater than 0.99 in the linear section. The method was proven by forced degradation studies carried out under acidic, basic, oxidative, thermal, and photolytic methods. The procedure is inexpensive, simple, and compliant with regulations. The procedure is suitable for the Tizanidine Hydrochloride bulk drug and pharmaceutical implementations."
Disclaimer: Curated by HT Syndication.
